National Comprehensive Cancer Network

Members Only
NCCN Oncology Research Program (ORP)
ORP Recent News
ORP Affiliate Research Consortium
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources (Members Only
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

NCCN Pfizer Inc. Clinical Pathways in Breast Cancer Program Grant Opportunity – Submit Letter of Intent (LOI) by Monday, June 26, 2017

National Comprehensive Cancer Network® (NCCN®) is pleased to announce it is collaborating with Pfizer’s Independent Grants for Learning & Change (IGLC) team to offer a new grant opportunity seeking proposals that use clinical pathways to address a quality improvement (QI) initiative along the continuum of care for breast cancer patients. The Request for Proposals (RFP) clearly outlines the scope and process that will be followed for the submission of Letters of Intent (LOIs). 

The intent of the RFP is to encourage organizations to submit LOIs describing concepts and ideas for developing, implementing and evaluating guideline based clinical pathways in breast cancer.

NCCN views this collaboration with Pfizer’s IGLC team as clear recognition of the advantages offered to industry and organizations treating cancer patients through the NCCN Oncology Research Program. We hope you and your colleagues will be interested in this opportunity.

LOIs are due by 11:59 PM EDT, Monday, June 26, 2017. If you have any questions regarding this RFP, please direct them in writing to the Pfizer Grant Officer for this clinical area, Jacqueline Waldrop at Jacqueline.waldrop@pfizer.com with the subject line, “2017 Clinical Pathways in Breast Cancer.”

View RFP

Pfizer, Inc. Grant Application System